Data from a phase 2 study (NCT03824483) support the use and further investigation of the frontline BOVen regimen consisting of zanubrutinib (Brukinsa), obinutuzumab (Gazvya), and venetoclax (Venclexta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback